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Background: Disturbance in sleep quality is a symptom of Major Depressive Disorder (MDD) and Bipolar Disorder
(BD) and thus improving quality of sleep is an important aspect of successful treatment. Here, a prospective,
double-blind, randomized, placebo-controlled study examined the effect of olanzapine (an atypical antipsychotic)
augmentation therapy on sleep architecture, specifically slow wave sleep (SWS), in the treatment of depression.
The effect of olanzapine augmentation therapy on other features of sleep (e.g., sleep continuity) and depression
(e.g., illness severity and cognitive function) were also determined.
Methods: Patients currently experiencing a major depressive episode and who were on a stable medication were
included. Sleep architecture was measured by overnight ambulatory polysomnography. Illness severity was
determined using the Montgomery-Asberg Depression Rating Scale (MADRS). Cognitive function was examined
using Cambridge Neuropsychological Test Automated Battery (CANTAB): Spatial Working Memory (SWM), Spatial
Span (SSP), and Reaction Time (RTI) tasks. Polysomnographs, clinical measures and cognitive tests were administered
at baseline, after 2–4 days of treatment and after 28–31 days of treatment. Twenty-five patients participated in the
study (N = 10, N = 15 for placebo and olanzapine treated groups respectively).
Results: The primary objective of the study was to assess the objective (polysomnographic) changes in sleep
quality, defined as changes in SWS, following olanzapine treatment for depression. Latency to but not duration of
SWS was found to significantly differ between olanzapine- and placebo-treated participants (Hedge’s g: 0.97, 0.13
respectively). A significant improvement in olanzapine-treated participants over placebo-treated participants was
observed in secondary outcome measures, including sleep efficiency, total sleep time, and sleep latency. Secondary
objectives assessed the subjective changes in sleep quality parameters and correlated them with measures of illness
severity and changes in cognition. MADRS scores were significantly improved in olanzapine-treated participants
over time but not more than placebo treatment. There was no significant difference between olanzapine- and
placebo-treated participants in SWM, SSP or RTI tasks.
Conclusions: Olanzapine augmentation treatment generally did not improve SWS but did improve sleep continuity
and depression. Olanzapine may be one of few medications that improve sleep continuity, thus directly targeting
symptoms of depression.
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Disturbance in sleep quality is a symptom of Major
Depressive Disorder (MDD) and Bipolar Disorder (BD)
[1], with MDD having the strongest association with
sleep disturbances [2,3]. It is well documented that the
severity of the sleep disturbance is related to treatment
response, as well as the chronicity of the disorders [4,5],
and as such, is an important aspect of treatment.
Sleep has two main components: Rapid Eye Movement
(R) and Non-REM (N) sleep [6]. N sleep includes stages
1 to 3, where stage 3 is referred to as slow wave sleep
(SWS). SWS is considered the deepest stage of sleep and
involves a higher arousal threshold [7]. This is the most
prevalent stage of the sleep cycle in the first third of the
night, approximately 10%-15% of total sleep time (TST).
As SWS shortens in each cycle, the amount of R sleep
increases, with R sleep being most prevalent during each
cycle in the final third of the night, constituting 20%-25%
of TST [6].
Sleep architecture in patients experiencing depression
is generally thought to be altered [8]. Sleep during
depressive episodes is characterized by a reduction in
SWS, or increased latency to SWS, increased duration of
R sleep, shortened latency to R sleep, continuity distur-
bances, and decreased TST [9-12]. Altered SWS and R
sleep are seen in approximately 50% of patients with
affective disorders [12]. Sharpley et al. [13], found a
negative association between SWS activity and illness
severity of depression; however, variables such as sleep
efficiency and TST were also found to significantly
increase as illness severity decreased.
Cognitive deficits in MDD and BD include working
memory, attention and psychomotor speed [14-18].
Acute and chronic sleep deprivation has been shown to
affect attention, working memory and cognitive function
[19-22]. In healthy volunteers, SWS deprivation was
associated with impaired cognitive performance and a
delayed reaction time upon awakening [23,24]. In
particular, studies have shown that duration of SWS per
night is correlated with working memory performance
in elderly and schizophrenic samples [25,26]. However,
the role of sleep in the cognitive performance of patients
with mood disorders is unknown.
Monoaminergic neurotransmitters are thought to be
involved in the relationship between sleep and depression.
The serotonergic [27,28], cholinergic [6], histaminergic
[29,30], and noradrenergic [27] systems all contribute to
the pathophysiology of depression and the underlying
mechanisms of sleep. Antidepressants can produce changes
in the sleep electroencephalogram (EEG) of depressed
patients, the most prominent being the suppression of
R sleep. This is thought to occur by increasing nor-
epinephrine (NA) and/or serotonin (5-HT) function
[31]. 5-HT receptors have also been shown to play acritical role in the regulation of SWS. Several antidepres-
sants, particularly tricyclic antidepressants and trazodone,
are thought to normalize SWS because of their affinity for
5-HT2A and 5-HT2C receptors [31].
It has been estimated that up to 30% of patients with
depression fail to respond to traditional antidepressant
treatments alone [32]. Augmentation of antidepressant
therapy, with olanzapine, an atypical antipsychotic, is
often used in routine clinical practice for the treatment
of depression. Olanzapine has affinity for dopamine
D1, D3, and D4; serotonin 5-HT2A/C, 5-HT3 and 5-HT-6;
muscarinic M1-M5; adrenergic α1; and histamine H1
receptors. Moreover, olanzapine is an antagonist at
these sites, with highest affinity for both the dopamine
and serotonin receptors [33].
To date, many studies have focused on improving
illness severity of patients with MDD or BD by combin-
ing mood stabilizing medication with a change in sleep-
related behaviours [34-36]. A review by Riemann et al.
[8] described several different interventions used to
improve sleep habits of patients with MDD, such as
psychotherapy [37], pharmacological treatment [38], and
sleep deprivation therapy [39], among others. A large
majority of these studies, regardless of treatment type,
found that improving sleep continuity measures resulted
in improvements in mood. Olanzapine has been shown
to increase sleep continuity, subjective sleep measures
and SWS in healthy volunteers [40-42] while an associ-
ation between changes in sleep architecture and mood
improvement in patients with MDD remains unclear
[13]. Finally, Olanzapine has also been shown to improve
cognition in schizophrenic patients [43]; however, its
impact on cognition in depressive patients has not yet
been fully described.
The primary aim of this study was to examine the
effects of olanzapine augmentation treatment on sleep
architecture, specifically SWS, in patients experiencing a
major depressive episode. Furthermore, we examined
several secondary outcome measures to determine the
effects of olanzapine augmentation on other elements
of sleep, like TST and sleep continuity, and aspects of
depression, including illness severity and cognitive
function.
Methods
The present study was a prospective, double-blind,
placebo-controlled, repeated measures, polysomnographic
study. This study was approved by the Queen’s University
research ethics board, Health Canada, and was registered
with clinicaltrials.gov (NCT00520507).
Participants
A 15% change in the primary outcome measure, SWS,
was selected to be a clinically significant and meaningful
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indicating that 30 participants (15 placebo, 15 treatment)
were needed to have enough power to detect an effect of
olanzepine on SWS. To account for drop-outs, we aimed
to enroll 40 participants. The trail was stopped, however,
before reaching recruitment goals (May 2009) due to
an inability to recruit participants. Only thirty-one
participants signed informed consent to participate in
this study.
Participants were screened and enrolled into the study
(beginning October 2007) by blinded clinicians (nurses)
and recruited from tertiary care mood disorders units,
general practitioners offices, and from the community.
All were 18 years of age or older, and met DSM-IV-TR
criteria [44] for MDD, Bipolar I Disorder, Bipolar II
Disorder or Bipolar Disorder NOS, as confirmed by the
Mini International Neuropsychiatric Inventory (MINI)
[45]. At enrollment, participants were experiencing a
major depressive episode (MDE), defined as a Hamilton
Depression Rating Scale-17 item (HDRS-17) score
of >15, and not a mixed episode, defined as a Young
Mania Rating Scale Score (YMRS) of ≤ 12 [46]. Excluded
criteria were current or past diagnosis of schizophrenia
or dementia, substance abuse within three months of
enrolment (excluding caffeine or nicotine), imminent
risk of suicide or danger to themselves or others, known
intolerance for olanzapine, a serious or inadequately
treated medical illness, a history of seizures, previous
enrollment in the study or enrollment in another treat-
ment study within 4 weeks prior. Participants could not
be taking any other antipsychotic medication at the
time of enrolment and must have been on a stable
dose of all medications for 4 weeks prior to enrolment.
Benzodiazepines and other sleep aids were discontinued if
a stable dose had not been achieved for four weeks
prior to enrolment (number of participants on each
concomitant drug: Placebo: 1 Remeron, 2 Prozac, 1
Valproic Acid, 2 Clonazepam, 1 Lorazepam, 1 Trazodone,
1 Citalopram, 1 bupropion, 1 fluvoxamine, 1, cipralex, 1
oxycontin, 1 Ativan, 1 Topamax, 1 fluvianzine; Olanzepine:
2 Remeron, 2 Prozac, 1 doxepine, 1 amitriptyline,1
oxazepam, 5 Clonazepam, 1 ritalin, 1 Lorazepam, 1
lithium, 1 immovane 1 Citalopram, 2 bupropion, 1
fluvoxamine, 2 cipralex, 2 Effexor). Four participants
failed baseline screening (1 had a HAMD score that
was too low, 1 was already receiving olanzepine treatment
[and also had a too-low HAMD score], and 2 failed to
show at the screening appointment) and two participants
withdrew (refused to continue to participate) between
randomization and day 2–4, and were not included in
the analysis. Thus, 25 participants were included in
the analysis. Three participants from the olanzapine-treated
group terminated from the study before day 28–31, due to
a worsening of original mood symptoms. Participants weremonitored for sleep apnea and/or hypopnea throughout
the course of the study as the presence of these conditions
at any point warranted exclusion from the study due to the
confounding nature of these events on sleep architecture.
No participants needed to be removed due to obstructive
sleep apnea/hypopnea.
Clinical measures
Participants were assessed at three time-points by a
clinician blinded to treatment group: baseline (before
randomization and administration of study medication),
2–4 days, and 28–31 days after the administration of study
medication. Each clinical assessment consisted of the
HDRS-17 [47], the Montgomery Asberg Depression
Rating Scale (MADRS) [48], the Hamilton Anxiety Rating
Scale (HARS) [49,50], the YMRS [46], the Pittsburgh Sleep
Quality Index (PSQI) [51], Visual Analogue Scale (VAS)
for sleep quality [52], and the Epworth Sleepiness
Scale (ESS) [53]. At baseline, the MINI and the Clinical
Global Impression-Severity (CGI-S) [54], scales were
administered. During day 28–31, the Clinical Global
Impression-Improvement (CGI-I) was administered.
Baseline blood work, physical exam, and pregnancy test
(in women of childbearing potential) were performed.
Neurocognitive measures
At each visit, participants completed cognitive testing using
three Cambridge Neuropsychological Test Automated
Battery (CANTAB) tasks, including: Spatial Span (SSP),
Spatial Working Memory (SWM) and Reaction Time
(RTI) [55,56] (Cambridge Cognition, Cambridge, UK;
www.camcog.com). One participant did not complete
the CANTAB testing.
Medication
Participants were randomly assigned to either placebo or
olanzapine (orally disintegrating, zydis, formulation)
conditions. A randomization table was generated by
a statistician to randomize for order that then placed
sealed envelopes containing a single allocation (A:Placebo,
B:Olanzapine) into a box in the order specified by the
randomization table. Following screening, the participant
was instructed to pull the next envelope in the box. This
allocation was given to an unblinded pharmacist who
filled a prescription that read ‘placebo/olanzapine.’
Medication dosing started at 2.5 mg on day 1 and
increased to 5 mg at day 2; during day 2–4, the
dosing was titrated up or down, in increments of
2.5 mg to a maximum of 20 mg. The mean dose of
olanzapine was 6.67 mg at the end of the study; doses
ranged from 5 mg to 10 mg. Eight participants in the
placebo-treated group and twelve in the olanzapine-
treated group were taking at least one antidepressant as
concomitant medications; concomitant antidepressants







Male 5 (50) 6 (40)
Female 5 (50) 9 (60)
Diagnosis (%) 1.0
MDD 5 (50) 7 (47)
BD 5 (50) 8 (53)
Age (±SD) 46 (9) 46 (17) 0.24
Weight (±SD) Visit 1 185 (50) 178 (36) 0.76
Visit 4 185 (51) 182 (37)
MDD =Major Depressive Disorder, BD = Bipolar Disorder. P-value reported for
the test statistic for Fisher’s Exact Test (gender and diagnosis) and between
groups ANOVA and repeated measures ANOVA (age and weight, respectively).
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lopram, doxepine, venlafaxine, fluoxetine, remeron,
and trazodone. One participant in the placebo-treated
group was taking only a benzodiazepine; one partici-
pant in the ola\nzapine-treated group was only taking
one mood stabilizer; one participant in the placebo-
treated group and two in the olanzapine-treated group
were not taking any other psychotropic medications. All
concomitant medications were stable throughout the
duration of the study.
Polysomnographic recordings
At each time-point, an overnight sleep polysomnograph
(PSG) was performed by a clinician blinded to treatment
group at the participants’ home, using the MediPalm
Personal Recording Device (Braebon Medical Corporation,
Kanata, Ontario, Canada). The overnight sleep PSG
included four electroencephalogram channels (C4-A1,
C3-A2, O2-A1, O1-A2 [57]), an electro-oculogram
(two channels), a submental electromyogram (EMG), a fin-
ger pulse oximetry, an oronasal airflow (oronasalthermistor),
a chest and abdominal movement belt (respiratory
inductance plethysmography), a vibration snore sensor
and an anterior tibialis EMG. A position sensor was
used to monitor position continuously (Ultima Body
Position Sensor; Braebon Medical Corporation, Carp,
Canada). Participants were not monitored in person.
Sharpley et al. [31,58,59] have demonstrated that the
use of home sleep recordings provides a reliable means of
detecting the effects of medications on sleep architecture.
Once the PSG was applied (approximately 1900 hrs each
study night), a timer was set to record for eight hours fol-
lowing usual sleep time or until the participant rose in the
morning. Usual sleep time was verbally confirmed for each
participant. Participants were asked to retire and rise at
their usual time and were to refrain from alcohol on study
nights; however, normal caffeine and nicotine intake was
maintained. While participants did not all go to bed at the
same time, eight hours or less was sufficient sleep time for
those enrolled. Clinicians returned in the morning
(following the participants’ usual wake time) to retrieve
the PSG equipment. Sleep latencies were calculated from
lights out. PSGs were manually scored in 30-second
epochs according to standardized criteria of American
Academy of Sleep Medicine [60], using Pursuit Advanced
Sleep System software (Braebon Medical Corporation,
Carp, Canada). Ruehland et al. [61] have demonstrated
that measures of sleep architecture are not affected by the
number of EEG electrode placements used in scoring the
PSG. Technicians were blinded to treatment status. Only
one PSG recordings was excluded from analysis due to
technical problems. Obstructive apneas and hypopneas,
defined as partial airway obstructions leading to a 50%
reduction in thoracoabdominal movement lasting for atleast 10 seconds [62], were scored using the criteria from
the American Academy of Sleep Medicine Task Force
[63]. Arousals were scored based on American Sleep
Disorders Association criteria, 1992 [57]. The respiratory
disturbance index (RDI), which included apneas,
hypopneas, and snore arousals for the number of
events per hour of sleep, were calculated.
Statistical analysis
PSG recording and clinical measures (with the exception
of the CGI) were analyzed using 2-way and 1-way
repeated measures analysis of variance (ANOVA). The de-
sign included two treatment groups (placebo × olanzapine)
across three time-points (baseline, Day 2–4 and Day
28–31). Independent-samples t-tests examined post-hoc
comparisons. Hedge’s g was used to calculate the effect
size of the primary outcome measure, changes in SWS,
between groups on Day 28–31. Missing PSG, clinical and
CANTAB data were replaced with the last observation
carried forward. One participant did not complete any of
the CANTAB and was not included for this analysis.
One-tailed distributions were used for all clinical
measures, while for polysomnographic and neurocognitive
measures, two-tailed distributions were used. Additionally,
demographic comparisons between groups were analyzed
using Fisher’s exact tests or ANOVAs (see Table 1). For
repeated-measures ANOVA, trend analyses (contrasts)
were performed and reported. Neither sphericity of
variance nor a significant main effect of the within-subject
variable is an assumption of running trend analysis.
Results
Twenty-five participants were included in the analysis
(N = 15 olanzepine and N = 10 placebo treated). The
mean (±SD) age of the olanzapine-treated group and
placebo-treated group was 46 ± 17 years (range: 20–59,
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respectively and did not differ significantly between the
treatment groups (see Table 1).
Polysomnographic measures
Table 2 summarizes all primary and secondary polysomno-
graphic outcome measures for sleep architecture, in both
olanzapine and placebo groups, across baseline, day 2–4,
and day 28–31. Figure 1 shows the percentage of TST spent
in SWS and latency to SWS in both olanzapine- and
placebo-treated groups. A 2-way repeated measures
ANOVA did not yield significant changes in percentage of
TST spent in SWS between the olanzapine- or placebo-
treated group (F[1,23] =2.36; p = 0.138; Hedge’s g = 0.53)
across time (F[1,23] =0.256; p = 0.775). Latency to SWS
significantly decreased with olanzapine treatment by the
end of the trial (no main effect of treatment, F[1,23] = 2.49,
p = .128; significant interaction of time x treatment,
F[1,23] = 5.49, p = 0.028). Comparing the two treatment
groups at each time point indicated that at the beginning
of the trial latency to SWS was not different (t[23] = −.192,Table 2 Polysomnographic measures
Sleep parameter Placebo
Baseline Day 2-4 Day 28-
Mean ± SD
Sleep continuity
Total time in bed (min) 468 ± 27 454 ± 37 458 ± 30
Total sleep time (min) 315 ± 62 307 ± 58 289 ± 75
Total wake time (min) 153 ± 67 148 ± 63 169 ± 75
No. of awakenings 29 ± 18 23 ± 9 26 ± 11
No. of stage changes 145 ± 77 125 ± 50 123 ± 50
Respiratory disturbance index 15 ± 14 13 ± 12 8.7 ± 7.2
Sleep efficiency 67 ± 14 68 ± 14 63 ± 17
Sleep architecture
Latency to sleep (min) 76 ± 61 86 ± 67 92 ± 78
Latency to Stage 1 (min) 67 ± 54 73 ± 51 85 ± 77
Duration of Stage 1 (min) 36 ± 28 30 ± 16 31 ± 16
Duration of Stage 1 (% of TST) 11 ± 8.0 10 ± 4.5 11 ± 5.0
Latency to Stage 2 (min) 82 ± 68 92 ± 72 96 ± 81
Duration of Stage 2 (min) 168 ± 62 160 ± 62 166 ± 58
Duration of Stage 2 (% of TST) 53 ± 13 51 ± 12 56 ± 12
Latency to R (min) 212 ± 88 220 ± 89 277 ± 25
Duration of R (min) 59 ± 20 66 ± 27 48 ± 28
Duration of R (% of TST) 19 ± 5.9 22 ± 7.8 16 ± 7.5
Latency to SWS (min) 112 ± 75 116 ± 14 172 ± 12
Duration of SWS (min) 48 ± 34 47 ± 31 43 ± 27
Duration of SWS (% of TST) 17 ± 13 18 ± 13 17 ± 14
The mean ± standard deviation (SD) of sleep parameters for both olanzapine and p
REM = Rapid Eye Movement. P value reported for the interaction (time by treatmenp = .849) but by Day 28–31, the olanzapine treated group
reached SWS faster than the placebo group (t[23] = 2.42,
p = 0.024; hedges g = 0.97). Latency to sleep however, was
not significantly different and could not account for
decreased latency to SWS in the olanzapine treated group
(no main effect of treatment F[1,23] = 2.17, p = 0.154 or
time F[1,23] = 0.297, p = .591). Duration of SWS was also
not significantly affected by the olanzapine treatment
compared to placebo (F[1,23] =0.581; p = 0.454) over
time (F[1,23] = 0.00; p = 0.984; Hedge’s g = 0.13).
TST and Sleep efficiency are shown in Figure 2 for
both olanzapine- and placebo-treated groups. Two two-
way repeated-measures ANOVA showed an increase in
TST (trend for main effect of treatment, F[1,23] = 3.69,
p = 0.067) and sleep efficiency (main effect of treatment,
F[1,23] = 5.10, p = 0.034) of the olanzapine-treated group
compared to the placebo-treated group. Both TST and
sleep efficiency demonstrated significant time x treatment
interactions (TST: F[1,23] = 4.58; p = .043; sleep efficiency:
F[1,23] = 5.27, p = 0.031). Post-hoc independent-samples
t-tests were conducted to analyze the nature of theseOlanzapine
31 Baseline Day 2-4 Day 28-31 ANOVA
Mean ± SD
460 ± 41 457 ± 32 461 ± 32 p = .523
326 ± 168 383 ± 66 363 ± 89 p = .043
135 ± 107 74 ± 68 80 ± 63 p = .023
18 ± 7.0 13 ± 4.9 15 ± 7.1 p = .775
99 ± 36 101 ± 44 98 ± 38 p = .254
13 ± 21 11 ± 25 12 ± 25 p = .126
71 ± 23 84 ± 14 83 ± 13 p = .031
69 ± 83 38 ± 50 41 ± 45 p = 0.069
72 ± 74 42 ± 42 45 ± 41 p = .073
32 ± 18 25 ± 12 27 ± 10 p = .984
11 ± 11 6.5 ± 2.8 7.2 ± 3.5 p = .353
79 ± 86 46 ± 59 47 ± 49 p = .058
199.3 ± 69.3 230.7 ± 55.4 230 ± 55 p = .048
57 ± 12 60 ± 12 60 ± 10 p = .927
0 165 ± 132 184 ± 100 180 ± 97 p = .552
77 ± 50 82 ± 37 87 ± 39 p = .285
20 ± 12 21 ± 7.7 22 ± 8.4 p = .239
4 121 ± 122 59 ± 64 77 ± 70 p = .028
28 ± 25 44 ± 48 38 ± 43 p = .295
10 ± 12 12 ± 12 10 ± 12 p = .994
lacebo treated group. TST = Total Sleep Time, SWS = Slow Wave Sleep,
t) of a two-way repeated measures ANOVA.
Figure 1 Latency to slow wave sleep and percentage of slow wave sleep. A) Mean ± standard error of the mean for latency to slow wave
sleep (SWS) in minutes, for both olanzapine- and placebo-treated groups for each time. B) Percentage of SWS measured by ratio of SWS within
total sleep time (TST) in minutes. *p = 0.024 between placebo and olanzapine groups on Day 28–31.
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or sleep efficiency at baseline (TST: t23 = −0.325, p = 0.798;
Sleep efficiency: t23 = −0.460, p = 0.65) but by Day 28–31
olanzapine treatment significantly increased both
(TST: t23 = −2.21; p = 0.037; Sleep efficiency: t23 = −3.30;
p = 0.003).
As well as an increase in TST, olanzapine treated
participants experienced significantly fewer awakenings
(Table 2) and less overall time awake compared to treatment
with placebo (2-way repeated measures ANOVA; main
effect of treatment, number of awakenings, F[1,23] = 10.0,
p = 0.004; awake time, F[1,23] = 4.8, p = 0.037). Post-hoc
analysis of the significant interaction of time by treatment
in awake time (F[1,23] = 4.93, p = 0.037) indicated that at
baseline, awake times did not differ between placebo and
olanzapine-treated participants (t23 = 0.531, p = 0.601) but
by Day 28–31, olanzapine treatment was significantly
decreasing amount of awake time participants experienced
(t23 = 2.26, p = 0.003).
Two-way repeated measures ANOVA also analyzed
the percentage of TST spent in R and duration of R
(Table 2). There was neither a main effect of treatmentFigure 2 Sleep continuity. A) Total sleep time B) Sleep efficiency. Mean ±
groups. Total sleep time is measured in minutes. Sleep efficiency: % = total
olanzapine groups on Day 28–31.or time on percentage of TST spent in R (F[1,23] = .796,
p = 0.382; F[1,23] = .025, p = 0.875, respectively. There
was a significant effect of olanzapine treatment on
duration of R (F[1,23] = 4.78, p = 0.039) however there
was neither a significant effect of time (F[1,23] = .003,
p = 0.957) or a significant interaction of treatment by
time (F[1,23] = .696, p = 0.413). Furthermore, Table 2
means indicate that the olanzapine group showed longer
R than the placebo group even at baseline, suggesting that
the difference in R sleep was not due to the addition of
olanzapine.
Measures
Clinical measures are included as results of a secondary
objective of the study. Figure 3 shows the mean MADRS
total scores for both olanzapine- and placebo-treated
participants. Two-way repeated ANOVA showed no
significant differences between olanzapine and placebo
treatment for MARDS or HDRS scores (F[1,23] = 1.09,
p = .306; F[1,23] = 0.269, p = .609, respectively). However,
both MARDS and HDRS scores significantly decreased
with time (F[1,23] = 6.03, p = .022; F[1,23] = 20.0, p = <.001,standard error of the mean for both olanzapine- and placebo-treated
sleep time(TST)/time in bed (TIB)× 100. *p < .05 between placebo and
Figure 3 Montgomery-Asberg Depression Rating Scale. Total
score with mean ± standard error of the mean for both olanzapine- and
placebo-treated groups. *p < .001 for olanzapine groups across time.
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showed a significant decrease in total MADRS score
from baseline to the end of the trial (day 28–31) for
olanzapine-treated patients (main effect of time: F
[1,14] = 6.03, p = .022), where as placebo treatment did
not show a decrease (F[1,9] = 0.529, p = .486). HDRS
scores also significantly decreased over time in the
olanzapine-treated group (F[1,14] =19.6, p = .001), but the
placebo-treated group did not (F[1,9] =4.67, p = .059).
Table 3 shows clinician administered and self report rating
scale scores for both the olanzapine- and placebo-treated
groups.
Neurocognitive measures
Neurocognitive measures, evaluated as mean CANTAB
testing scores, are shown in Table 4 and were assessed
as a secondary objective of the study. The between




Baseline Day 2-4 Day 28-31
Mean ± SD
MADRS total 26 ± 6.3 26 ± 7.1 24 ± 3.2
HDRS total 21 ± 5.5 19 ± 5.9 18 ± 7.4
HARS total 16 ± 2.9 13 ± 4.7 13 ± 5.3
YMRS total 3.9 ± 3.4 3.7 ± 2.5 4.7 ± 4.2
PSQI total 13 ± 3.0 14 ± 3.6 12 ± 5.2
VAS total 31 ± 15 32 ± 19 43 ± 27
ESS total 7.4 ± 6.2 5.4 ± 4.2 5.8 ± 5.9
The mean ± standard deviation (SD) of selected clinical measures for both olanzapin
Rating Scale, HDRS = Hamilton Depression Rating Scale, HARS = Hamilton Anxiety Ra
sleep quality, PSQI = Pittsburg Sleep Quality Index, ESS = Epworth Sleepiness Scale.
measures ANOVA.both the olanzapine- and placebo-treated groups did
not significantly change between groups (F[1,22] = 0.3,
p = 0.590; F[1,22] = 0.658, p = 0.426, respectively) or across
time (F[1,22] = 1.4, p = 0.242; F[1,22] = 0.713, p = 0.407,
respectively). The mean spatial span length recalled on the
CANTAB SSP task was also not significantly different
between treatment groups or across time (2-way re-
peated measures ANOVA, F[1,22] = 0.102, p = 0.753;
F[1,22] = 0.036, p = 0.852, respectively). Finally, the
mean reaction time and movement time from the
CANTAB RTI task for both the olanzapine- and
placebo-treated groups also showed no significant changes
as a result of olanzapine treatment (2-way repeated mea-
sures ANOVA reaction time and movement: treamt-
ment, F[1,22] = 0.089, p = .768; F[1,22] = 0.15, p = .702,
respectively) or over time (2-way repeated measures
ANOVA reaction time and movement: time, F[1,22] = 2.28,
p = .145; F[1,22] = 2.57, p = .123, respectively).
Discussion
Surprisingly, the addition of olanzapine to the current
medication regimes of patients experiencing either
unipolar or bipolar major depressive episodes only
resulted in significant improvements in latency to SWS
but not in other SWS measures, the primary outcome
measure of this study. However, olanzapine augmentation
did significantly improve the secondary outcome measure
sleep continuity, that included sleep efficiency, number of
awakenings, time spent awake and total sleep time. These
improvements did not extend to significant changes other
aspects of sleep architecture, like percentage of R sleep.
Treatment with olanzapine also significantly improved
illness severity without changes in measures of executive
and psychomotor function.
To date, Sharpley et al. [13] have reported the only
study to investigate the addition of olanzapine to SSRI
treatment on overnight polysomnograph in patients withOlanzapine
Baseline Day 2-4 Day 28-31 ANOVA
Mean ± SD
25 ± 5.8 23 ± 6.2 19 ± 11 p = .175
22 ± 5.0 18 ± 6.4 15 ± 8.4 p = .123
17 ± 5.8 15 ± 7.4 13 ± 6.7 p = .420
3.7 ± 3.1 2.9 ± 3.0 3.5 ± 2.3 p = .223
12 ± 3.5 11 ± 4.2 9.9 ± 4.7 p = .699
37 ± 27 45 ± 28 59 ± 30 p = .415
8.4 ± 5.2 8.5 ± 5.6 7.3 ± 5.2 p = .666
e and placebo treated group. MADRS =Montgomery Asberg Depression
ting Scale, YMRS = Young Mania Rating Scale, VAS = Visual Analogue Scale for
P value reported for the interaction (time by treatment) of a two-way repeated




Baseline Day 2-4 Day 28-31 Baseline Day 2-4 Day 28-31 ANOVA
Mean ± SD Mean ± SD
SWM
Between errors 23 ± 26 22 ± 23 12 ± 15 34 ± 24 31 ± 19 21 ± 21 p = .778
Strategy score 29 ± 8.4 29 ± 7.6 28 ± 7.8 31 ± 8.0 30 ± 7.0 31 ± 6.9 p = .562
RTI
Reaction time 410 ± 80.6 395 ± 43.3 405 ± 52 410 ± 110 380 ± 92.8 388 ± 111 p = .333
Movement time 579 ± 110 567 ± 104 539 ± 61 542 ± 132 563 ± 136 530 ± 107 p = .395
SSP 5.8 ± 1.4 5.7 ± 1.6 5.6 ± 1.6 5.4 ± 1.4 5.4 ± 1.2 5.7 ± 1.4 p = .296
The mean ± standard deviation (SD) of cognitive measures for both olanzapine and placebo treated group.SWM = Spatial Working Memory task, RTI = Reaction
Time task, SSP = Spatial Span task. P value reported for the interaction (time by treatment) of a two-way repeated measures ANOVA.
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improvements in sleep efficiency, total sleep time,
percentage of time awake, total N percentage, subjective
sleep quality, a decrease in R percent, and an increased
R latency after a single dose of olanzapine. Our study
revealed similar improvements only for sleep continuity
measures and illness severity. We observed similar
improvements in HDRS scores. The study by Sharpley et al.
[13] included only patients with treatment resistant
(to SSRI’s) MDD, and olanzapine was administered
open-label with no control or comparison group. In
comparison, in our randomized, double-blind and placebo
controlled study, both patients with MDD and BD were
included, with most patients that were recommended to
receive augmentation to their antidepressant treatment
being treatment-resistant to SSRI’s. Thus, conflicting
findings may be due to the differences in the populations
studied and methodology.
Antidepressants rarely improve sleep continuity; most
improvements are seen with tricyclic antidepressants.
Increased total sleep time and sleep efficiency, as well as
decreased sleep latency and total wake time were
observed here, similar to that seen with other augmenta-
tion agents such as risperidone [64], but different than
quetiapine, which does not alter sleep continuity in
depression [65]. The beneficial effects of olanzapine
treatment on sleep continuity may be due to its diverse
pharmacological profile. Primarily, olanzapine is an
antagonist at 5-HT2A/C, 5-HT3 and 5-HT6 receptors
[33]. A reduction in serotonin firing rates allows for the
first sleep cycle to occur and serotonin suppresses R
sleep by inhibition of R-promoting cholinergic neurons
[6]. Olanzapine may also promote normalization of
sleep through antagonism of overactive cholinergic
neurons, as olanzapine has affinity for muscarinic
M1-M5 receptors. Cholinergic neurons are responsible for
the initial activation and ongoing generation of R
sleep [6]. Olanzapine also has moderate affinity for
the α-adrenergic1 receptor. The adrenergic system plays arole in the suppression of R and the promotion of sleep
cycles [6]. Finally, olanzapine also has affinity for the
histamine1 receptor. Histamine is thought to promote
wakefulness and reductions in histamine allow for sleep to
occur [29]. Therefore, olanzapine’s effects on neurotrans-
mitter systems important for normal sleep continuity
likely caused improvement in reported sleep continuity.
Few medications have been reliably shown to improve
SWS in the treatment of either unipolar or bipolar
depression. Only one randomized controlled trial
(RCT) examining the effects of trazodone on sleep
using polysomnography was identified. A study by
Saletu-Zyhlarz et al. [66] examined insomnia patients
with dysthymia and reported that trazodone administration
significantly increased latency to stage 3, time and percent-
age in stage 3, sleep efficiency, and number of awakenings.
A significant increase in the amount and percentage of R
sleep was also seen. Bemmel et al. [67] conducted a single
blind study of trazodone treatment on sleep architecture in
patients with MDD. They reported no improvements to
SWS and significant R suppression. In contrast, Mouret
et al. [68] examined the effects of open-label trazodone on
sleep in patients with MDD and reported significant
improvements in SWS and no effect on R sleep. A study by
Kluge et al. [69] examined the effects of duloxetine open-
label on sleep in MDD, and reported a significant improve-
ment in latency to SWS and time in SWS. Significant R
suppression was reported. No RCTs on the effects of dulox-
etine were identified. Antidepressants reliably suppress R
sleep; however, their effects on SWS are inconsistent in the
treatment of major depressive episodes.
Almost all antidepressants have been shown to suppress
R sleep by increasing the latency to R and decreasing the
total duration of R sleep. R suppression was not seen in
this study. Although expected, the lack of R suppression
may be due to the concomitant medications of the
participants. Only three participants were not taking
any other medications, 80% of participants were taking
at least one antidepressant, one participant was taking
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lithium only. Over 50% of participants were taking
more than one medication at enrolment into the
study. The antidepressant medications and lithium
may have suppressed R sleep and thus further suppression
of R sleep with the addition of olanzapine might have been
too minimal to detect. Although previous studies of
augmentation to SSRIs have shown R suppression, the
degree of polypharmacy was less in these studies, as each
participant was only taking one antidepressant [70]. This
may reflect the changes often seen with psychotropic
treatment to sleep architecture [65,71]. Few medications
have been reliably shown to suppress R sleep and also
increase sleep continuity and SWS. Many medications,
especially antidepressants, suppress R sleep and have
either no effect or detrimental effects on sleep continuity
or SWS. Also, several augmentation strategies, including
olanzapine, have been shown to improve sleep continuity
and SWS and have no effect on R sleep. Therefore, it is
plausible that R suppression and other changes in sleep
architecture are due to separate underlying mechanisms
and may need to be treated separately.
The improvement of depressive symptoms observed in
this study is representative of the effects of other atypical
antipsychotic agents in the treatment of depression, as
the olanzapine group had significantly greater improvement
than placebo in the MADRS score. The power of the study,
however, was not such as to determine efficacy. Clinical
response was seen in 46% of olanzapine-treated
patients while only 20% of placebo-treated patients did so.
Twenty-six percent of olanzapine-treated participants
reached remission and less than half of that (10%) in
the placebo group did so. Previously reported response
rates in a randomized double-blind study of olanzapine/
fluoxetine combination for the treatment of depression
are similar to what is observed here [36]. Significant
improvement in depressive symptoms with olanzapine/
fluoxetine combination versus placebo in the treatment of
bipolar disorder has been reported as well [72].
The literature on cognitive function in depression is
quite diverse and conflicting, as there seems to be no
clear pattern of dysfunction in MDD [14,73,74]. The lack of
changes seen here in working memory or psychomotor
function was not unexpected. Impairments seen in neuro-
cognitive tests in depression may be due to a lack of motiv-
ation to complete the task accurately and thus psychotropic
treatment or sleep normalization would not have an effect
on this beyond improvement of depressive symptoms. As
only 26% of our participants reached remission, many
participants had residual depressive symptoms and may not
have had an improvement in motivation. The lack of a
normal control group precludes us from reporting if the
level of baseline functioning is within the normal range or
is impaired and did not improve with treatment.There are a number of limitations in this study. First,
participants were maintained on a large variety of
concomitant medications. This likely contributed to the
highly variable effect of olanzapine on SWS. Secondly,
there were a large number of secondary outcome
measures and a relatively small sample size. This is most
relevant to the lack of change seen in SWS, R sleep and
on the neurocognitive measures. A larger sample size
may also lend itself to a more precise differentiation
between placebo- and olanzapine-treated participants on
improvements in subjective sleep quality. Furthermore,
the duration of this study only permitted evaluation of the
short-term treatment of depression; it is well understood
that to observe full improvement with many different
psychotropic medications 6–8 weeks or even longer is
needed. Finally, the results of this study are generalizable
to a select number of patient populations, as there were
some comorbid exclusions and a variety of concomitant
medications. For instance, the results of this study do not
allow us to understand what effect olanzapine may have on
sleep architecture in patients with comorbid substance
abuse. Further studies should evaluate the influence of
different dosages and long-term studies are needed to see
if improvements continue into treatment maintenance.
Conclusions
Olanzapine augmentation in the treatment of both unipolar
and bipolar depression resulted in significant improvements
in sleep continuity, total sleep time and latency to sleep
onset as well as significantly improved depressed mood.
However, significant changes were only moderately seen in
SWS and not at all in R sleep. Olanzapine has been shown
to increase SWS in other psychiatric disorders, e.g.,
schizophrenia [75]. Factors as simple as dosage of olanza-
pine may moderate affects on SWS across patient popula-
tions. Furthermore, even within patient populations much
of the literature shows conflicting results [66-71] of olanza-
pine on sleep architecture. Changes in cognition, both
working memory and psychomotor function, were not
observed. However, olanzapine may be one of few medica-
tions that improve sleep continuity, thus directly targeting
symptoms of depression. Olanzapine may produce this
effect through its high affinity for not only serotonin recep-
tors but also muscarinic, adrenergic and histaminergic
receptors. The heterogeneity of this study population allows
for generalizability to clinical populations, and as such
olanzapine may be an effective tool in the treatment of
sleep dysfunction in depression.
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